Anil Singhvi recommends these 4 stocks for short-term gains today; check target prices and stop-loss levels

At a time when Global cues are strong along with hope from Domestic equities, Market Expert Anil Singhvi has chosen four fundamentally strong stocks for a potential up move as the market opens today. Singhvi identified these stocks as being potentially strong fundamentally based on solid quarterly performances, technical set-up, and strong sector triggers. Here's the full buy strategy with stop loss and target levels.

Varun Beverages: Uptrend intact, global rating upgrade further fuels rally
Buy (Futures)

• Stop Loss: Rs 471
• Target: Rs 487 / Rs 494 / Rs 500

The stock is in a strong uptrend and has a strong fundamental base. The global brokerage Goldman Sachs has a 'Buy' rating and a target price of Rs 600, as the stock has very attractive valuations at 40 times FY27 earnings which is below the stapler sector's multiples. The low per capita consumption of ready-to-drink beverages in India provides long-term expansion potential. As an important Pepsi bottler, Varun Beverages is well-positioned to benefit from this consumption boom.

Motherson: Bonus buzz sets sthe tage for breakout
Buy call (Futures)

• Stop Loss: Rs 148
• Target: Rs 153 / Rs 157 / Rs 159

Singhvi is positive on Motherson at the moment, due to the company's stock being viewed favourably to a proposed bonus issue (the board meets on May 29). The speculative trigger has good momentum, and a bonus issue could lead to a breakout in this stock.

Bayer CropScience: Q4 metrics raise concerns
Cash Buy Recommendation

Stop Loss: Rs 5,020
Target: Rs 5,200 / Rs 5,350 / Rs 5,450 

Bayer CropScience posted a strong Q4, with EBITDA up 75 per cent to Rs 170.8 crore. Margins improved from 12.3 per cent to 16.3 per cent, revenue rose by 32.1 per cent and profit growth was 49.3 per cent! Given such positive operating performance, the momentum remains positive 

Akums Drugs: Loss to profit, turnaround play
Buy Call (Cash)

• Stop Loss: Rs 572
• Target: Rs 590 / Rs 595 / Rs 605

Another turnaround play involved Akums Drugs as the company posted a net profit of Rs 148 crore for Q4FY25 from a loss of Rs 41 crore in the previous quarter. Further, EBITDA improved sharply from Rs 2 crore to Rs 95 crore with margins increasing from 0.2 per cent to 8.9 per cent indicating significant operational performance.

Given strengthened technicals, fundamental resilience, and sectoral tailwinds, the overall impression is positive for these four stocks in the short term. Traders can use a tight stop loss and be guided by the selling targets as per Singhvi’s strategy.